GlassScriptPhysician profile
Aytan Mammadova
NPI 1437503976
$7,879.67
in general payments reported to CMS, 2019-2025
39 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $588 · 2023: $1,803 · 2024: $3,052 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,291.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,712.35 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $645.80 | 2023-2025 | |
| Corcept Therapeutics | $536.78 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.37 | 2022-2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $471.54 | 2022-2025 | Unithroid |
| Novo Nordisk INC | $463.47 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $461.03 | 2022-2025 | |
| Abbott Laboratories | $421.08 | 2023-2025 | Freestyle Libre 3, Freestyle Libre, Proclaim |
| Mannkind Corporation | $383.16 | 2023-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $364.27 | 2022-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Cequr Corporation | $354.59 | 2023-2025 | Cequr Simplicity |
| Amgen INC. | $168.82 | 2022-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $150.78 | 2024-2025 | |
| Dexcom, INC. | $126.14 | 2023-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $116.84 | 2024-2025 | Isturisa, Signifor Lar |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $109.20 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Antares Pharma, INC. | $94.21 | 2024-2025 | Xyosted |
| Alexion Pharmaceuticals, INC. | $93.76 | 2024-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $87.35 | 2023-2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $58.67 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $57.57 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $44.01 | 2022-2025 | Farxiga |
| Insulet Corporation | $42.06 | 2024 | Omnipod |
| Astellas Pharma US INC | $41.68 | 2024-2025 | Veozah |
| Medtronic, INC. | $41.01 | 2023-2025 | Minimed 780g |
| Averitas Pharma INC. | $32.82 | 2025 | Qutenza |
| Tolmar, INC. | $29.00 | 2023-2024 | |
| Biomarin Pharmaceutical INC. | $27.10 | 2022 | |
| Radius Health, INC. | $27.08 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $25.69 | 2024 | Crysvita |
| Chiesi USA, INC. | $23.86 | 2025 | Mycapssa |
| Ibsa Pharma INC. | $22.63 | 2024 | Licart, Tirosint |
| Pfizer INC. | $21.69 | 2023 | |
| Endo Pharmaceuticals INC. | $20.49 | 2023 | Aveed |
| Madrigal Pharmaceuticals | $18.38 | 2025 | Rezdiffra |
| Rhythm Pharmaceuticals, INC. | $16.88 | 2025 | Imcivree |
| Ascensia Diabetes Care US INC. | $16.32 | 2023 | |
| Esperion Therapeutics, INC. | $16.07 | 2025 | Nexletol |
| Acella Pharmaceuticals, LLC | $14.12 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aytan Mammadova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.